India Compulsory Licensing: What USTR Hearing Transcripts Say
This article was originally published in PharmAsia News
Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.
You may also be interested in...
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”